| DrugRepV_1562 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (93 %) | Approved, Investigational | 26217313 |
| DrugRepV_1563 | Masitinib | Antineoplastic and Immunomodulating Agents | Mast cell tumors in dogs | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (84 %) | Investigational, Vet approved | 26217313 |
| DrugRepV_1564 | Desmethyl Erlotinib | NA | Cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (65 %) | Approved, Investigational | 26217313 |
| DrugRepV_1565 | Pazopanib Hydrochloride | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (61 %) | Approved | 26217313 |
| DrugRepV_1566 | Paclitaxel | Antineoplastic and Immunomodulating Agents | Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (78 %) | Approved | 26217313 |
| DrugRepV_1567 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (61 %) | Approved | 26217313 |
| DrugRepV_1568 | Docetaxel | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (45 %) | Approved | 26217313 |
| DrugRepV_1569 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (72 %) | Approved, Investigational | 26217313 |
| DrugRepV_1570 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (68 %) | Approved | 26217313 |
| DrugRepV_1571 | Fulvestrant | Antineoplastic and Immunomodulating Agents | Breast cancer | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (43 %) | Approved, Investigational | 26217313 |
| DrugRepV_1572 | Fenbendazole | Antiparasitic products, Insectisides and Repellents | Helminthiasis | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (81 %) | Vet approved | 26217313 |
| DrugRepV_1573 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (57 %) | Approved, Investigational, Vet approved | 26217313 |
| DrugRepV_1574 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (86 %) | Approved | 26217313 |
| DrugRepV_1575 | Teniposide | Antineoplastic and Immunomodulating Agents | Acute lymphoblastic leukaemia | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (57 %) | Approved | 26217313 |
| DrugRepV_1576 | Itraconazole | Antiinfectives For Systemic Use | Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis) | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (74 %) | Approved, Investigational | 26217313 |
| DrugRepV_1577 | Clotrimazole | Dermatologicals | Fungal infections | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (33 %) | Approved | 26217313 |
| DrugRepV_1578 | Clemastine Fumarate | Respiratory System | Allergic rhinitis | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (63 %) | Approved | 26217313 |
| DrugRepV_1579 | Manidipine Dihydrochloride | Cardiovascular agents | Hypertension | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (63 %) | Approved, Investigational | 26217313 |
| DrugRepV_1580 | Floxuridine | Anticancer | Gastrointestinal adenocarcinomas | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (45 %) | Approved | 26217313 |
| DrugRepV_1581 | Maprotiline Hydrochloride | Nervous System | Bipolar depression | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (41 %) | Approved, Investigational | 26217313 |
| DrugRepV_1582 | Quetiapine Fumarate | Nervous System | Schizophrenia | Bipolar disorder | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (41 %) | Approved | 26217313 |
| DrugRepV_1583 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (2 to 3 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1584 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (2 to 3 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1585 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rZH548 | NA | Plaque assay | Decrease (4 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1586 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (50 %) | Approved, Investigational | 26217313 |
| DrugRepV_1587 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (50 %) | Approved, Investigational | 26217313 |
| DrugRepV_1588 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | NA | NA | Real-time PCR | Decrease | Approved, Investigational | 26217313 |
| DrugRepV_1589 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (90 %) | Approved, Investigational | 26217313 |
| DrugRepV_1590 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Luciferase reporter assay | Decrease (90 %) | Approved, Investigational | 26217313 |
| DrugRepV_1591 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (3 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1592 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4 Logs reduction) | Approved | 26217313 |
| DrugRepV_1593 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4.5 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1594 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4.5 Logs reduction) | Approved | 26217313 |
| DrugRepV_1595 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (1 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1596 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (1 Logs reduction) | Approved | 26217313 |
| DrugRepV_1597 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1598 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (3 Logs reduction) | Approved | 26217313 |
| DrugRepV_1599 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (5 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1600 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4 Logs reduction) | Approved | 26217313 |
| DrugRepV_1601 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (3 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1602 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (6 Logs reduction) | Approved | 26217313 |
| DrugRepV_1603 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (2 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1604 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (2 Logs reduction) | Approved | 26217313 |
| DrugRepV_1605 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (4 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1606 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (5 Logs reduction) | Approved | 26217313 |
| DrugRepV_1607 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (93 %) | Approved, Investigational | 26217313 |
| DrugRepV_1608 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (100 %) | Approved | 26217313 |
| DrugRepV_1609 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | rMP12 | NA | Plaque assay | Decrease (97 %) | Approved, Investigational | 26217313 |
| DrugRepV_1610 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Survival assay | No significant effect | Approved, Investigational | 26217313 |
| DrugRepV_1611 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Real-time PCR | Decrease (2 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1612 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Real-time PCR | Decrease (2 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1613 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Real-time PCR | Decrease (0.4 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1614 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | ZH501 | NA | Plaque assay | Decrease (1.9 Logs reduction) | Approved, Investigational | 26217313 |
| DrugRepV_1964 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (70 %) | Approved, Investigational | 28794043 |
| DrugRepV_3623 | Benzodiazepine | Nervous System | Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease. | Rift Valley fever virus | MP12 | NA | qRT-PCR | Decrease (50 %) | Approved, Investigational | 27654301 |
| DrugRepV_3648 | 2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine | NA | NA | Rift Valley fever virus | MP12 | NA | Luciferase assay | Decrease (50 %) | NA | 21270170 |
| DrugRepV_3678 | NSC 62914 | NA | NA | Rift Valley fever virus | MP12 | NA | RT-PCR | Decrease (97 %) | NA | 22027648 |
| DrugRepV_3691 | BCX4430 | NA | Ebola virus | Rift Valley fever virus | ZH5018 | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3711 | C795-0925 | NA | NA | Rift Valley fever virus | ZH548/MP-12 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3712 | D011-2120 | NA | NA | Rift Valley fever virus | ZH548/MP-12 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3713 | F694-1532 | NA | NA | Rift Valley fever virus | ZH548/MP-12 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3714 | G202-0362 | NA | NA | Rift Valley fever virus | ZH548/MP-12 | NA | RT-PCR | Decrease (50 %) | NA | 25144302 |
| DrugRepV_3861 | Favipiravir | Antiviral | Influenza virus | Rift Valley fever virus | MP12 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Investigational | 27736754 |
| DrugRepV_4319 | FGI-106 | NA | NA | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (50 %) | NA | 19523489 |
| DrugRepV_5141 | PF-4708671 | NA | NA | Rift Valley fever virus | MP12ΔNSs-Luc | NA | Luciferase assay | Decrease (50 %) | NA | 29652799 |
| DrugRepV_5142 | Pteridinone | NA | NA | Rift Valley fever virus | MP12ΔNSs-Luc | NA | Luciferase assay | Increase (50 %) | NA | 29652799 |
| DrugRepV_5143 | PF-4708671-BI-D1870 | NA | NA | Rift Valley fever virus | MP12ΔNSs-Luc | NA | Luciferase assay | Decrease (50 %) | NA | 29652799 |
| DrugRepV_5144 | SB203580 | NA | NA | Rift Valley fever virus | MP12ΔNSs-Luc | NA | Luciferase assay | Decrease (50 %) | NA | 29652799 |
| DrugRepV_5145 | PD0325901 | NA | Melanoma | Solid Tumour | Solid Tumors | Advanced Cancer | Breast Neoplasms | Rift Valley fever virus | MP12ΔNSs-Luc | NA | Luciferase assay | Decrease (50 %) | Investigational | 29652799 |
| DrugRepV_5146 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | MP12ΔNSs-Luc | NA | Luciferase assay | Decrease (50 %) | Approved, Investigational | 29652799 |
| DrugRepV_5147 | Rapamycin-SB203580 | NA | NA | Rift Valley fever virus | MP12ΔNSs-Luc | NA | Luciferase assay | Decrease (50 %) | NA | 29652799 |
| DrugRepV_5148 | Rapamycin-PD0325901 | NA | NA | Rift Valley fever virus | MP12ΔNSs-Luc | NA | Luciferase assay | Decrease (50 %) | NA | 29652799 |
| DrugRepV_5149 | PF-4708671 | NA | NA | Rift Valley fever virus | MP12 | NA | Western blot | Decrease | NA | 29652799 |
| DrugRepV_5150 | PF-4708671 | NA | NA | Rift Valley fever virus | MP12 | NA | Plaque assay | No significant effect (0.5 log pfu/ml) | NA | 29652799 |
| DrugRepV_5151 | PF-4708671-BI-D1870 | NA | NA | Rift Valley fever virus | MP12 | NA | Western blot | Decrease | NA | 29652799 |
| DrugRepV_5152 | PF-4708671-BI-D1870 | NA | NA | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (2 log pfu/ml) | NA | 29652799 |
| DrugRepV_5153 | SB203580 | NA | NA | Rift Valley fever virus | MP12 | NA | Western blot | No significant effect | NA | 29652799 |
| DrugRepV_5154 | SB203580 | NA | NA | Rift Valley fever virus | MP12 | NA | Plaque assay | No significant effect (<0.5log pfu/ml) | NA | 29652799 |
| DrugRepV_5155 | PD0325901 | NA | Melanoma | Solid Tumour | Solid Tumors | Advanced Cancer | Breast Neoplasms | Rift Valley fever virus | MP12 | NA | Western blot | Decrease | Investigational | 29652799 |
| DrugRepV_5156 | PD0325901 | NA | Melanoma | Solid Tumour | Solid Tumors | Advanced Cancer | Breast Neoplasms | Rift Valley fever virus | MP12 | NA | Plaque assay | No significant effect (0.5log pfu/ml) | Investigational | 29652799 |
| DrugRepV_5157 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (2log pfu/ml) | Approved, Investigational | 29652799 |
| DrugRepV_5158 | Rapamycin-SB203580 | NA | NA | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (>3log pfu/ml) | NA | 29652799 |
| DrugRepV_5159 | Rapamycin-PD0325901 | NA | NA | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (3log pfu/ml) | NA | 29652799 |
| DrugRepV_5160 | Benzavir-2 | NA | NA | Rift Valley fever virus | rRVFV?NSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 29386590 |
| DrugRepV_5161 | Benzavir-1 | NA | NA | Rift Valley fever virus | rRVFV?NSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 29386590 |
| DrugRepV_5162 | 2-[[4-chloro-2-[(2-fluorobenzoyl)amino]benzoyl]amino]benzoic acid | NA | NA | Rift Valley fever virus | rRVFV?NSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 29386590 |
| DrugRepV_5163 | 2-[[2-(2,2-dimethylpropanoylamino)benzoyl]amino]benzoic acid | NA | NA | Rift Valley fever virus | rRVFV?NSs::Katushka | NA | Fluorescence-based assay | No significant effect (50 %) | NA | 29386590 |
| DrugRepV_5164 | 2-[[2-(cyclohexanecarbonylamino)benzoyl]amino]benzoic acid | NA | NA | Rift Valley fever virus | rRVFV?NSs::Katushka | NA | Fluorescence-based assay | No significant effect (50 %) | NA | 29386590 |
| DrugRepV_5165 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | MP12-Luc | NA | Luciferase assay | Decrease (50 %) | Approved, Investigational | 28442428 |
| DrugRepV_5166 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | MP12 | NA | Western blot | Decrease | Approved, Investigational | 28442428 |
| DrugRepV_5167 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (2 log pfu/ml) | Approved, Investigational | 28442428 |
| DrugRepV_5168 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | ZH501 | NA | Plaque assay | Decrease (1 log pfu/ml) | Approved, Investigational | 28442428 |
| DrugRepV_5169 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | MP12 | NA | Real-time PCR | Decrease (2 log Genomic Copies) | Approved, Investigational | 28442428 |
| DrugRepV_5170 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Rift Valley fever virus | ZH501 | NA | Survival assay | Increase | Approved, Investigational | 28442428 |
| DrugRepV_5171 | 3-(2,3-Diphenyl-1H-indol-1-yl)-N-(3-hydroxybenzylidene) propanohydrazide | NA | NA | Rift Valley fever virus | rRVFVΔNSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 26762502 |
| DrugRepV_5172 | 1-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-(2-imino-3-(4-methylbenzyl)-2,3- dihydro-1H-benzimidazol-1-yl)ethanone hydrobromide | NA | NA | Rift Valley fever virus | rRVFVΔNSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 26762502 |
| DrugRepV_5173 | 4-Hydroxy-3-methoxybenzaldehyde (4-(3,4-dimethoxyphenyl)-6-phenyl-2- pyrimidinyl)hydrazone | NA | NA | Rift Valley fever virus | rRVFVΔNSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 26762502 |
| DrugRepV_5174 | 1-(3,4-Dichlorophenyl)-3-(4-(3,4-dimethoxyphenyl)-1-methylpyrrolidin-3- yl)urea | NA | NA | Rift Valley fever virus | rRVFVΔNSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 26762502 |
| DrugRepV_5175 | 2-Chloro-N-(2-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-ylcarbamoyl)phenyl) benzamide | NA | NA | Rift Valley fever virus | rRVFVΔNSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 26762502 |
| DrugRepV_5176 | 2-(4-Bromo-5-chlorothiophene-2-sulfonamido)-N-(4-fluorophenyl) benzamide | NA | NA | Rift Valley fever virus | rRVFVΔNSs::Katushka | NA | Fluorescence-based assay | Decrease (50 %) | NA | 26762502 |
| DrugRepV_5177 | Suramin | Antiparasitic products, Insectisides and Repellents | Sleeping sickness | Onchocerciasis | Rift Valley fever virus | MP12 | NA | Fluorescence-based assay | Decrease (1 log Resazurin fluorescence) | Investigational | 25267680 |
| DrugRepV_5178 | Suramin | Antiparasitic products, Insectisides and Repellents | Sleeping sickness | Onchocerciasis | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease | Investigational | 25267680 |
| DrugRepV_5179 | Suramin | Antiparasitic products, Insectisides and Repellents | Sleeping sickness | Onchocerciasis | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (50 %) | Investigational | 25267680 |
| DrugRepV_5180 | C795-0925 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5181 | D011-2120 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5182 | F694-1532 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5183 | G202-0362 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5184 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5185 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5186 | C795-0925 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5187 | D011-2120 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5188 | F694-1532 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5189 | G202-0362 | NA | NA | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25144302 |
| DrugRepV_5190 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5191 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Rift Valley fever virus | ZH501 | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 25144302 |
| DrugRepV_5206 | Favipiravir | Antiviral | Influenza virus | Rift Valley fever virus | ZH501 | NA | Survival assay | Increase | Investigational | 24722586 |
| DrugRepV_5207 | Favipiravir | Antiviral | Influenza virus | Rift Valley fever virus | ZH501 | NA | Plaque assay | Decrease | Investigational | 24722586 |
| DrugRepV_5208 | Curcumin | NA | Depressive disorder | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (3 log pfu/ml) | Approved | 22847000 |
| DrugRepV_5209 | SC-514 | NA | NA | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (<1 log pfu/ml) | NA | 22847000 |
| DrugRepV_5210 | Curcumin | NA | Depressive disorder | Rift Valley fever virus | ZH501 | NA | Plaque assay | Decrease (4 log pfu/ml) | Approved | 22847000 |
| DrugRepV_5211 | Curcumin | NA | Depressive disorder | Rift Valley fever virus | MP12 | NA | Plaque assay | Decrease (5 log pfu/ml) | Approved | 22847000 |
| DrugRepV_5212 | Suramin Sodium | Antiparasitic products, Insectisides and Repellents | Sleeping sickness | Onchocerciasis | Rift Valley fever virus | NA | NA | RVFV nucleocapsid (N) protein RNA-binding activity | Decrease (50 %) | Investigational | 22644268 |
| DrugRepV_5213 | Quinacrine Dihydrochloride | NA | Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions | Rift Valley fever virus | NA | NA | RVFV nucleocapsid (N) protein RNA-binding activity | Decrease (50 %) | Investigational | 22644268 |
| DrugRepV_5214 | N-methyl-2,3-diphenyl-1,2,4-thiadiazol-5-imine;hydrobromide | NA | NA | Rift Valley fever virus | NA | NA | RVFV nucleocapsid (N) protein RNA-binding activity | Decrease (50 %) | NA | 22644268 |
| DrugRepV_5215 | 4-(3,6-dioxocyclohexa-1,4-dien-1-yl)benzoic acid | NA | NA | Rift Valley fever virus | NA | NA | RVFV nucleocapsid (N) protein RNA-binding activity | Decrease (50 %) | NA | 22644268 |
| DrugRepV_5216 | BTB 11461 | NA | NA | Rift Valley fever virus | NA | NA | RVFV nucleocapsid (N) protein RNA-binding activity | Decrease (50 %) | NA | 22644268 |
| DrugRepV_5217 | Ammonium Chloride | Blood and Blood Forming Organs; Genito Urinary System and Sex Hormones | NA | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | Decrease (90.3 %) | Approved | 21994655 |
| DrugRepV_5218 | Guanidine | Musculo-Skeletal System | Muscle weakness | Myasthenic syndrome of Eaton-Lambert | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | No significant effect (54.2 %) | Approved | 21994655 |
| DrugRepV_5219 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | Decrease (87.2 %) | Approved | 21994655 |
| DrugRepV_5220 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | Decrease (86.8 %) | Approved | 21994655 |
| DrugRepV_5221 | Monensin | Antibiotics | Bacterial infections | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | Decrease (97.9 %) | Experimental, Vet approved | 21994655 |
| DrugRepV_5222 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Rift Valley fever virus | RVF-VLPs | NA | RLuc expression | Decrease (91.1 %) | Approved | 21994655 |
| DrugRepV_5223 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | rMP12-rLuc | NA | Plaque assay | Decrease (>2 log pfu/ml) | Approved | 19197350 |
| DrugRepV_5224 | Actinomycin D | Antineoplastic and Immunomodulating Agents | Cancer | Rift Valley fever virus | MP12 | NA | Plaque assay | No significant effect (NA pfu/ml) | Approved | 19197350 |
| DrugRepV_5391 | Quinacrine | NA | Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions | Rift Valley fever virus | NA | NA | NA | Decrease (50 %) | Investigational | 31307979 |